Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical enti...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

1 Adelaide Street East, Suite 801, Toronto, Canada

Doggsy May. 19 at 6:14 PM

$QNTM i can see this breaking 7$ today setting up a run to 8 later in the week. Has turned from one of my worst new holdings to the best. Hope the court case turns out well for us. GLTA longs.

0 · Reply

STACKD0E May. 19 at 5:58 PM

$QNTM

0 · Reply

Smartacusnot May. 19 at 5:42 PM

$QNTM

0 · Reply

PatriotAmbassador May. 19 at 8:24 AM

$QNTM a nice spike in sp is coming 👊

0 · Reply

Rambler1111 May. 18 at 11:25 PM

$QNTM Pleasantly surprised at the after hours comeback, hopefully bigger and better tomorrow morning.

0 · Reply

rockitpicks May. 18 at 11:15 PM

$QNTM This is setting up for a good $10 pop

0 · Reply

Boomer10 May. 18 at 10:18 PM

$QNTM Really moving after hours today.

0 · Reply

NetworkNewsWire May. 18 at 7:28 PM

BioMedNewsBreaks – $QNTM $QNTM.CN Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study https://ibn.fm/GAecM

0 · Reply

Vapor83 May. 18 at 6:15 PM

$QNTM those who knocked this down from $38 are close to their own death rattle - don’t be surprised at the coming valuation

0 · Reply

ZacksResearch May. 18 at 4:27 PM

$QNTM just hit a major MS milestone — and the imaging data could be a game changer 🔬 Quantum BioPharma’s study with Massachusetts General Hospital has reached the halfway enrollment mark, with early PET imaging data showing robust signal in acute MS lesions and potential sensitivity to gray matter lesions. 🧠 The [¹⁸F]3F4AP PET tracer could enable direct tracking of demyelination and myelin repair in real time 📈 That may strengthen development of Lucid-MS, Quantum’s investigational therapy targeting PAD2 to prevent and reverse myelin breakdown 🚀 Phase 2 IND submission was already sent to the FDA in March 2026 See what Wall Street expects next 👉 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-38124&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_38124

0 · Reply